About the Clinical Research Unit Groningen

About CRU Groningen

The new Clinical Research Unit (CRU) Groningen is the result of a unique partnership between ICON, a global commercial CRO, and the University Medical Centre Groningen (UMCG) an academic hospital located in the center of Groningen. The UMCG is one of the largest hospitals in the Netherlands and the largest employer in the Northern Netherlands. More than 13,000 employees provide patient care, are involved in medical education and perform cutting-edge scientific research, focused on ‘healthy and active ageing’. The CRU Groningen offers the opportunity to carry out early and late phase clinical research in patients with various medical conditions as well as the execution of clinical trials that incorporate particularly invasive or specialized assessments in healthy volunteers. The CRU Groningen is being built on the UMCG site, ensuring direct access to hospital care and is equipped for intensive monitoring and (poli) clinical treatments. The CRU will be operational in the first quarter of 2022.

The goal

In the CRU Groningen, investigational medicinal products (IMPs) can be tested in patients at an early stage in development and therefore potentially accelerating the overall timelines for that compounds development. The CRU Groningen has been designed and organized in accordance with good clinical practice (GCP) to accommodate the delivery of complex clinical trials through all phases of research.

Your research in the CRU

Do you want to know more about the possibilities for your research in the CRU Groningen?

CRU facilities

The CRU Groningen has a variaty of patient and research facilities.

Our research projects

Do you want to read more about our current research project? Read about them here!

Unique collaboration

This unique collaboration between the UMCG and ICON results in a purpose-built unit, combining the expertise and infrastructure of an academic hospital and the commercial focus of a renowned clinical research organization. As partners we enhance the quality of early phase studies performed within the UMCG, as well as provide the opportunity for ICON to conduct early phase studies with moderate and severe patients and studies with invasive assessments. Combining knowledge and expertise acts as a catalyst for the rapid, innovative and high-quality development of medicines: healthcare improves research, and research improves healthcare. This will, of course, benefit both research and patient.